MARKET

SYK

SYK

Stryker
NYSE

Real-time Quotes | Nasdaq Last Sale

233.19
+2.19
+0.95%
Opening 11:03 12/02 EST
OPEN
231.03
PREV CLOSE
231.00
HIGH
233.19
LOW
229.55
VOLUME
172.79K
TURNOVER
--
52 WEEK HIGH
242.51
52 WEEK LOW
124.54
MARKET CAP
87.63B
P/E (TTM)
50.50
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
20 Most Diverse Cities in the U.S.
In this article we take a look at the 20 most diverse cities in the US. Click to skip ahead and jump to the 10 most diverse cities in the US. Diversity is one of the most important topics right now, especially in the US. Tensions between different races have never been higher and there […]
Insider Monkey · 11/25 14:56
Stryker prices $600M debt offering
Stryker (SYK) has priced $600M of its 0.600% notes due December 1, 2023.Offering of the Notes is expected to close on November 23. Net proceeds will be used for general corporate
Seekingalpha · 11/19 10:56
Baird draws positive reads from early optimism in health system CFO survey
Baird's survey of health systems CFOs (80 of them, representing about $76B in annual revenue and about 84,000 licensed inpatient beds) points to a somewhat upbeat mood for 2021. Comps
Seekingalpha · 11/18 23:39
Stryker announces pricing of $600 million senior notes offering
Kalamazoo, Michigan, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) (the “Company”) announced today that it has priced an offering of $600 million aggregate principal amount of its 0.600% Notes due 2023 (the “Notes”). Unless previously redeemed pursuant to their terms, the Notes will mature on December 1, 2023. The offering of the Notes is expected to settle on November 23, 2020, subject to the satisfaction of customary closing conditions.The Company intends to use the net proceeds from the offering for general corporate purposes, which may include payments in connection with the redemption of Wright Medical Group N.V.’s (“Wright”) convertible debt, which the Company assumed upon completion of the acquisition of Wright.Citigroup Global Markets Inc., BofA Securities, Inc. and Wells Fargo Securities, LLC are acting as active joint book-running managers for the offering. The offering is being made pursuant to a preliminary prospectus supplement, filed today, to the Company’s prospectus, dated February 7, 2019, filed as part of the Company’s effective shelf registration statement. Copies of the preliminary prospectus supplement and accompanying prospectus relating to the Notes may be obtained by contacting: Citigroup Global Markets Inc. toll-free at 1-800-831-9146, BofA Securities, Inc. toll-free at 1-800-294-1322 and Wells Fargo Securities, LLC toll-free at 1-800-645-3751 or wfscustomerservice@wellsfargo.com.This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. Forward-looking statementsThis press release contains information that includes or is based on forward-looking statements within the meaning of the federal securities laws that are subject to various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements. Such factors include, but are not limited to: the impact on our operations and financial results of the COVID-19 pandemic and any related policies and actions by governments or other third parties; unexpected liabilities, costs, charges or expenses in connection with the acquisition of Wright; the effects of the Wright transaction on the parties' relationships with employees, customers, other business partners or governmental entities; weakening of economic conditions that could adversely affect the level of demand for our products; pricing pressures generally, including cost-containment measures that could adversely affect the price of or demand for our products; changes in foreign exchange markets; legislative and regulatory actions; unanticipated issues arising in connection with clinical studies and otherwise that affect U.S. Food and Drug Administration approval of new products, including Wright products; potential supply disruptions; changes in reimbursement levels from third-party payors; a significant increase in product liability claims; the ultimate total cost with respect to recall-related matters; the impact of investigative and legal proceedings and compliance risks; resolution of tax audits; the impact of the federal legislation to reform the United States healthcare system; costs to comply with medical device regulations; changes in financial markets; changes in the competitive environment; our ability to integrate and realize the anticipated benefits of acquisitions in full or at all or within the expected timeframes, including the acquisition of Wright; and our ability to realize anticipated cost savings. Additional information concerning these and other factors is contained in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that affect the likelihood that actual results will differ from those contained in the forward-looking statements.About StrykerStryker is one of the world’s leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes.ContactsFor investor inquiries please contact: Preston Wells, Vice President, Investor Relations at 269-385-2600 or preston.wells@stryker.comFor media inquiries please contact: Yin Becker, Vice President, Communications, Public Affairs and Corporate Marketing at 269-385-2600 or yin.becker@stryker.com
GlobeNewswire · 11/18 22:00
Stryker to participate in the 3rd Annual Evercore ISI HealthCONx Virtual Conference
Kalamazoo, Michigan, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the 3rd Annual Evercore ISI HealthCONx Virtual Conference on Thursday, December 3, 2020.Preston Wells, Vice President, Investor Relations and Spencer Stiles, Group President, Orthopaedics and Spine, will represent the Company in a presentation scheduled for 8:00 a.m. Eastern Time.A simultaneous webcast and replay of the Company's presentation will be available on Stryker's website at www.stryker.com. The webcast will be archived on the Investor Relations page of this site.Stryker is one of the world’s leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes. More information is available at www.stryker.com.ContactsFor investor inquiries please contact: Preston Wells, Vice President, Investor Relations at 269-385-2600 or preston.wells@stryker.com For media inquiries please contact: Yin Becker, Vice President, Communications, Public Affairs and Corporate Marketing at 269-385-2600 or yin.becker@stryker.com
GlobeNewswire · 11/17 14:30
Stryker Has a Bounce-Back Quarter
The company's most recent quarter was a return to growth
GuruFocus.com · 11/16 20:57
Colfax (CFX) Arm DJO Acquires Stryker's Extremity Products
Colfax (CFX) arm DJO closes buyout of products/system related to ankle replacement and finger arthroplasty from Stryker, which will boost its product offerings in the reconstructive products space.
Zacks · 11/13 14:24
Stryker elects Giovanni Caforio to Board of Directors
Kalamazoo, Michigan, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced today that Giovanni Caforio, M.D., Chairman and Chief Executive Officer of Bristol Myers Squibb, has been elected to its Board of Directors, effective December 1, 2020. “Giovanni adds extensive experience to our board as both a physician and business leader,” said Kevin Lobo, Chairman and Chief Executive Officer, Stryker. “As CEO of a leading global biopharmaceutical company, he has advanced scientific innovation that has helped improve the lives of patients. We look forward to welcoming Giovanni to our board.”Dr. Caforio has been CEO of Bristol Myers Squibb since May 2015 and assumed the role of Chairman of the Board in May 2017. As CEO, Dr. Caforio has led the company’s focus on researching and developing transformational medicines, which includes leading portfolios in oncology, hematology, immunology and cardiovascular disease. In 2019, he oversaw the acquisition of Celgene. Dr. Caforio joined Bristol Myers Squibb in 2000 and with his background as a physician has helped to strengthen the company’s patient-focused culture. Prior to that, he spent 12 years with Abbott Laboratories in a number of leadership positions. Dr. Caforio is the Chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA), a trade association representing pharmaceutical companies in the United States.“I am honored to join the Board of Directors for Stryker, a company with an impressive track record as a pioneer and leader in the medical technology space,” said Dr. Caforio. I am inspired by the company’s mission to make healthcare better and its focus on improving patient outcomes.”Stryker is one of the world’s leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes. More information is available at www.stryker.com.ContactsFor investor inquiries please contact: Preston Wells, Vice President, Investor Relations at 269-385-2600 or preston.wells@stryker.com For media inquiries please contact: Yin Becker, Vice President, Communications, Public Affairs and Corporate Marketing at 269-385-2600 or yin.becker@stryker.com
GlobeNewswire · 11/09 12:30
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SYK. Analyze the recent business situations of Stryker through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 28 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SYK stock price target is 226.91 with a high estimate of 258.00 and a low estimate of 194.00.
EPS
Institutional Holdings
Institutions: 1.84K
Institutional Holdings: 297.50M
% Owned: 79.17%
Shares Outstanding: 375.79M
TypeInstitutionsShares
Increased
522
9.40M
New
190
564.95K
Decreased
490
8.14M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.34%
Healthcare Equipment & Supplies
-0.17%
Key Executives
Chairman/Chief Executive Officer/Director
Kevin Lobo
President/Chief Operating Officer
Timothy Scannell
President/Chief Operating Officer
timothy Scannell
Chief Financial Officer/Vice President
Glenn Boehnlein
Corporate Executive
Viju Menon
Chief Human Resource Officer/Vice President
M. Kathryn Fink
Chief Accounting Officer/Vice President/Controller
William Berry
Chief Human Resource Officer/Vice President
M. Fink
Vice President/Director of Marketing
Yin Becker
Vice President/Director of Investor Relations
Preston Wells
Vice President
Robert Fletcher
Lead Director/Independent Director
Allan Golston
Independent Director
Mary Brainerd
Independent Director
Srikant Datar
Independent Director
Roch Doliveux
Independent Director
Sherilyn McCoy
Independent Director
Andrew Silvernail
Independent Director
Ronda Stryker
Independent Director
Rajeev Suri
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
07/30/2020
Dividend USD 0.575
09/29/2020
05/05/2020
Dividend USD 0.575
06/29/2020
02/05/2020
Dividend USD 0.575
03/30/2020
12/04/2019
Dividend USD 0.575
12/30/2019
07/31/2019
Dividend USD 0.52
09/27/2019
05/01/2019
Dividend USD 0.52
06/27/2019
02/06/2019
Dividend USD 0.52
03/28/2019
12/04/2018
Dividend USD 0.52
12/28/2018
--
Dividend USD 0.47
09/27/2018
05/02/2018
Dividend USD 0.47
06/28/2018
02/07/2018
Dividend USD 0.47
03/28/2018
12/06/2017
Dividend USD 0.47
12/28/2017
08/07/2017
Dividend USD 0.425
09/28/2017
05/16/2017
Dividend USD 0.425
06/28/2017
02/08/2017
Dividend USD 0.425
03/29/2017
12/08/2016
Dividend USD 0.425
12/28/2016
07/27/2016
Dividend USD 0.38
09/28/2016
04/27/2016
Dividend USD 0.38
06/28/2016
02/10/2016
Dividend USD 0.38
03/29/2016
12/10/2015
Dividend USD 0.38
12/29/2015
07/29/2015
Dividend USD 0.345
09/28/2015
04/29/2015
Dividend USD 0.345
06/26/2015
02/11/2015
Dividend USD 0.345
03/27/2015
12/04/2014
Dividend USD 0.345
12/29/2014
07/22/2014
Dividend USD 0.305
09/26/2014
04/22/2014
Dividend USD 0.305
06/26/2014
02/12/2014
Dividend USD 0.305
03/27/2014
12/05/2013
Dividend USD 0.305
12/27/2013
07/25/2013
Dividend USD 0.265
09/26/2013
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SYK
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company's segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products. The MedSurg segment includes surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling, emergency medical equipment, intensive care disposable products; reprocessed and remanufactured medical devices, and other related products. The Neurotechnology and Spine segment includes neurovascular products, spinal implant systems and other related products. The Company's products include implants, which are used in joint replacement and trauma surgeries, and other products that are used in a range of medical specialties.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Stryker Corporation stock information, including NYSE:SYK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SYK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SYK stock methods without spending real money on the virtual paper trading platform.